Entrinsic Health Solutions and Markey Cancer Center Launch Phase II Study for Neuroendocrine Tumor Patients with Quality of Life-Limiting Diarrhea

UF startup Entrinsic Health Solutions in partnership with the University of Kentucky (UK) Markey Cancer Center announced initiation of active accrual and first consented patient in its Phase II study evaluating enterade® – a glucose-free, medical food – in neuroendocrine tumor and carcinoid syndrome patients. Entrinsic Health Solutions is located in the UF Innovate | Sid Martin Biotech incubator.

Findings from this study may show that enterade can help maintain the small bowel’s ability to retain fluids leading to a reduction in stool frequency. The study will also examine the effects of enterade on patient-reported gastrointestinal symptoms and quality of life. 

Learn more about Entrinsic Health Solutions and Markey Cancer Center Launch Phase II Study for Neuroendocrine Tumor Patients with Quality of Life-Limiting Diarrhea.